Sirolimus Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028
Sirolimus, also known by its USAN-assigned generic name rapamycin, has gained traction in the medical and healthcare industries for its outstanding antitumor and immunosuppressive activities. Historically, researchers associated it with anticandida activity and hence for long utilized its potential as an antifungal agent. The sirolimus market has also attracted the interest of the medical community for its inhibitory role in antigen-induced proliferation of T cells, B cells, and antibody production. A growing body of animal studies in recent decades have confirmed this, and researchers continue to make strides in shedding light on the immunosuppressive therapeutic potential of sirolimus. The macrolide product has over the years has attracted interest of researchers for its promising potential in treating Lymphangioleiomiomatosis (LAM), rare, progressive cystic lung disease. It inhibits mammalian target of rapamycin, helping in stabilizing lung function.
The broad application areas in the sirolimus market are organ transplant rejection, catheter devices, lymphangioleiomyomatosis, and Sirolimus coated balloons. Major distribution channels are online pharmacies, hospital pharmacies, and retail pharmacies.
The relentless search for alternative immunosuppressive regimens in the past ten years has been one the trends driving the steady evolution of the sirolimus market. Since the beginning of the twenty-first century, a growing number of studies pertaining to de novo kidney transplant recipients have helped advance the potential of sirolimus in various therapies such as CNI minimization strategies along with mycophenolate (MMF/MPS). Growing populations in kidney transplant recipients has also stimulated industry funding in the sirolimus market. Researchers are trying continuously to evaluate its role in the rejection of kidney transplants, especially serious allograft dysfunction. The trend is imparting a significant impetus to the growth of the market.
Over the past few years, researchers have been striving to get a better understanding of the various mechanisms of SRL-associated adverse reactions. This is likely to expand the potential of the sirolimus market. Most prominently, a number of studies in recent years have looked into the efficacy and safety of sirolimus in lymphangioleiomyomatosis. Particularly, patients with preexisting glomerular diseases have been found to be at a significant risk. Such risk factors have made it difficult for interested companies to make rapid headways into the sirolimus market.
One of the key applications areas that industry players have been focusing is in making sirolimus-eluding stents. So promising is the potential that to cap opportunities in emerging markets, medical device makers want to avoid price caps. However, companies with this strategic motive have to move cautiously. A case in point is Meril Life Sciences, a Gujarat-based Indian company, has put second thoughts on claiming exemption from price controls for its sirolimus-drug eluding stent MeRes100. The regulator National Pharmaceutical Pricing Authority (NPPA), has deferred its appeal for the exemption, reason having to do with skepticism with the efficacy and safety of the Bioresorbable Vascular Scaffold stents.
Another area that might have transformative or disruptive effect is the long-term therapeutic potential of sirolimus in lymphangioleiomyomatosis. Though they slow down the disease progression, the findings of all major studies in recent years are neither consistent nor overwhelming, hindering the strides in the sirolimus market.
Some of the prominent players in the global sirolimus market are Intas Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Biocon, Dr. Reddy’s Laboratories Limited, Pfizer, Inc., Concept Medical, Inc., and Zydus Cadila.
Among the various key regions, North America has seemed to stay ahead of the pack. The growth has been supported by the vast uptake of advanced immunosuppressive therapies, especially with respect to kidney transplantation. Substantial studies over the past few years has helped enhance the role of the region in the global sirolimus market. Some of the other regional markets are Asia Pacific, Europe, the Middle East and Africa, and Latin America.
The study presents a granular assessment and quantitative evaluation of:
The region-wise assessment includes market dynamics in:
The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.
The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:
Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report